Asia Pacific (APAC) region contributed 21% of global revenue in 2016 and the region is expected to witness higher growth compared to other regions.
The company’s latest reveals that Japan will emerge as the major country in APAC region contributing 64% of the revenue in 2023. Japan contributed 62% of the revenue in the region in 2016 and during the forecast period, the market will grow at CAGR 4.2%.
The growth in the country is mainly attributed to higher usage of drug delivery systems in healthcare facilities, availability of reimbursement for majority of the population, increasing prevalence of chronic diseases (diabetes and cancer), growing geriatric population, increased understanding of drug metabolism and increased preference for individual and customized therapy especially for cancer.
Infusion systems and metered dose inhaler devices are the major revenue generators, while other segments in the market include central nervous catheters, needle free injections.
Infusion systems and metered dose inhaler devices generate 55.1% and 38.9% of the revenue.
Major companies having presence in the APAC drug delivery devices market include GlaxoSmithKline, Terumo Corp, AstraZeneca Plc, Boehringer Ingelheim GmbH, Baxter International and Pfizer Inc. These companies command 47% share in the APAC drug delivery devices market.
Delivering the active pharmaceutical ingredient to the specific target site is extremely important to get desired therapeutic result, but it is a complicated process. In past few decades, the innovation in drug delivery devices has simplified the process, helping achieve better therapeutic effects.
Once launched as drug carriers, these devices have now emerged as target-specific, dose-optimized systems with a higher level of safety and efficiency.
GlobalData analyst, Tina Deng said: “Drug delivery devices market is rapidly evolving because major pharmaceutical companies are designing their own drug delivery devices.
“This helps in gaining a strong market share; acts as a differentiator, and potentially as a patent extender. This allows technological innovations to grow and gives birth to strategic partnerships.”
According to , 61 drug delivery devices are in pipeline out of which 51.5% are in clinical stage and 36.8% are undergoing the approval process. Most of the pipeline products are aimed at treating cancer and pain disorders while others are focused on respiratory and neurological ailments.